Get the Stockscreener App
29.19
3.78%
-1.021
Rapt Therapeutics Inc stock is traded at $29.19, with a volume of 221.21K.
It is down -3.78% in the last 24 hours and down -3.55% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$30.21
Open:
$31.18
24h Volume:
221.21K
Relative Volume:
0.65
Market Cap:
$483.90M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-9.5702
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-3.43%
1M Performance:
-3.55%
6M Performance:
+275.84%
1Y Performance:
+62.94%
1-Day Range:
$29.00
$31.64
1-Week Range:
$29.00
$31.64
52-Week Range:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
29.26 | 751.36M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.41 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.28 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.19 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Can RAPT Therapeutics Inc. stock outperform in 2025 bull marketBreakout Watch & Weekly High Return Stock Forecasts - newser.com
Technical signs of recovery in RAPT Therapeutics Inc.Entry Point & AI Driven Stock Reports - newser.com
How RAPT Therapeutics Inc. stock benefits from tech adoptionJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Published on: 2025-11-03 08:21:37 - newser.com
Can RAPT Therapeutics Inc. (0RA) stock resist broad market declinesMarket Growth Review & Pattern Based Trade Signal System - newser.com
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaJobs Report & Smart Swing Trading Alerts - newser.com
Will RAPT Therapeutics Inc. (0RA0) stock outperform value peersOil Prices & Weekly Stock Performance Updates - newser.com
What to expect from RAPT Therapeutics Inc. in the next 30 daysTrade Entry Report & Fast Entry High Yield Stock Tips - newser.com
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherStop Loss & Verified Stock Trade Ideas - newser.com
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycleWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Can RAPT Therapeutics Inc. (0RA) stock attract ESG investments2025 Price Targets & Smart Swing Trading Techniques - newser.com
Is RAPT Therapeutics Inc. stock a buy for dividend growthIPO Watch & Advanced Swing Trade Entry Plans - newser.com
What makes RAPT Therapeutics Inc. stock attractive to growth funds2025 Market WrapUp & High Accuracy Trade Signal Alerts - newser.com
Why retail investors favor RAPT Therapeutics Inc. stockJuly 2025 Update & Daily Entry Point Alerts - newser.com
What institutional flow reveals about RAPT Therapeutics Inc.Market Risk Analysis & Growth Focused Stock Reports - newser.com
What drives RAPT Therapeutics Inc 0RA0 stock priceMomentum Trading Signals & High Return Trading Strategies - earlytimes.in
Is RAPT Therapeutics Inc. (0RA0) stock a buy before earnings resultsWeekly Risk Report & Target Return Focused Picks - newser.com
Is RAPT Therapeutics Inc. (0RA) stock dividend growth reliableJuly 2025 Selloffs & Weekly Momentum Picks - newser.com
RAPT Therapeutics, Inc. (RAPT) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
How institutional buying supports RAPT Therapeutics Inc. stockRate Cut & Reliable Intraday Trade Alerts - newser.com
Does RAPT Therapeutics Inc. (0RA) stock trade below intrinsic valueWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
How sentiment analysis helps forecast RAPT Therapeutics Inc.July 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
Analyzing RAPT Therapeutics Inc. with multi timeframe charts2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com
Tick level data insight on RAPT Therapeutics Inc. volatilityJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is RAPT Therapeutics Inc. stock reversal real or fake2025 Bull vs Bear & Comprehensive Market Scan Reports - newser.com
Risk adjusted return profile for RAPT Therapeutics Inc. analyzedJuly 2025 PostEarnings & Weekly High Return Opportunities - newser.com
Can RAPT Therapeutics Inc. recover in the next quarterJuly 2025 Sector Moves & Stock Portfolio Risk Management - newser.com
HC Wainwright Issues Pessimistic Estimate for RAPT Earnings - MarketBeat
Published on: 2025-10-31 05:54:11 - newser.com
Why RAPT Therapeutics Inc. (0RA) stock could break out in 2025July 2025 Recap & Fast Entry Momentum Alerts - newser.com
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):